新型吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Nov 14;15(12):2093-2094. doi: 10.1021/acsmedchemlett.4c00536. eCollection 2024 Dec 12.
Abstract
Provided herein are novel pyrrolidinone urea compounds as FPR2 agonists, pharmaceutical compositions, use of such compounds in treating atherosclerosis and heart failure, and processes for preparing such compounds.
摘要
本文提供了作为FPR2激动剂的新型吡咯烷酮脲化合物、药物组合物、此类化合物在治疗动脉粥样硬化和心力衰竭中的用途以及制备此类化合物的方法。
相似文献
1
Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2024 Nov 14;15(12):2093-2094. doi: 10.1021/acsmedchemlett.4c00536. eCollection 2024 Dec 12.
2
Novel Pyrrolidinone Urea as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型吡咯烷酮脲作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2025 Apr 21;16(5):756-757. doi: 10.1021/acsmedchemlett.5c00196. eCollection 2025 May 8.
3
Novel Carbocyclic Phenylpyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型碳环苯基吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2025 Jan 10;16(2):186-187. doi: 10.1021/acsmedchemlett.4c00614. eCollection 2025 Feb 13.
4
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
5
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的新型食欲素受体激动剂化合物。
ACS Med Chem Lett. 2024 Jul 3;15(8):1178-1179. doi: 10.1021/acsmedchemlett.4c00285. eCollection 2024 Aug 8.
6
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型苯基烷基胺作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12.
7
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.新型麦角灵类化合物作为5-羟色胺2A受体激动剂用于治疗情绪障碍
ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12.
8
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
9
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders.新型异色胺四环类化合物作为5-HT2A激动剂用于治疗脑部疾病。
ACS Med Chem Lett. 2025 May 9;16(6):933-934. doi: 10.1021/acsmedchemlett.5c00246. eCollection 2025 Jun 12.
10
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 13;16(6):929-930. doi: 10.1021/acsmedchemlett.5c00244. eCollection 2025 Jun 12.
引用本文的文献
1
Novel Carbocyclic Phenylpyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型碳环苯基吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2025 Jan 10;16(2):186-187. doi: 10.1021/acsmedchemlett.4c00614. eCollection 2025 Feb 13.
本文引用的文献
1
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease.血管炎症和动脉粥样硬化性心血管疾病中的特异性促解决介质。
Nat Rev Cardiol. 2024 Nov;21(11):808-823. doi: 10.1038/s41569-023-00984-x. Epub 2024 Jan 12.
2
The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists.甲酰肽受体 FPR1 和 FPR2 作为炎症性疾病的靶点：小分子激动剂研发的最新进展。
Eur J Med Chem. 2024 Feb 5;265:115989. doi: 10.1016/j.ejmech.2023.115989. Epub 2023 Nov 27.
3
Formyl peptide receptor 2 and heart disease.甲酰肽受体 2 与心脏疾病。
Semin Immunol. 2022 Jan;59:101602. doi: 10.1016/j.smim.2022.101602. Epub 2022 Mar 8.
Zotero 插件